close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Kodu・Aktsiate loetelu・Nektar Therapeutics
Search

Nektar Therapeutics

Suletud

91.27 -1.96

Tugev "osta" hinnang

Hinna uuendus 23. apr 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

87.11

Max

94.97

Põhinäitajad

By Trading Economics

Sissetulek

-557K

-36M

Müük

10M

22M

Aktsiakasum

-1.29

Kasumimarginaal

-165.447

Töötajad

63

EBITDA

10M

-19M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+48.48% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

944M

2.9B

Eelmine avamishind

93.23

Eelmine sulgemishind

91.27

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

0.5949 / 0.7406 Toetus ja vastupanu

Nektar Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

DJ

Loe

24. apr 2026, 00:00 UTC

Tulu

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

DJ

Loe

23. apr 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

DJ

Loe

23. apr 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

23. apr 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

23. apr 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

DJ

Loe

23. apr 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

DJ

Loe

23. apr 2026, 22:33 UTC

Tulu

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

DJ

Loe

23. apr 2026, 22:17 UTC

Tulu

PLS Executed Offtake Agreement With Ronbay

DJ

Loe

23. apr 2026, 22:17 UTC

Tulu

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

DJ

Loe

23. apr 2026, 22:16 UTC

Tulu

PLS Commences Commissioning of Midstream Demonstration Plant

DJ

Loe

23. apr 2026, 22:15 UTC

Tulu

PLS Group Reaffirms FY26 Guidance for All Metrics

DJ

Loe

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Margin From Operations A$461M at March 31

DJ

Loe

23. apr 2026, 22:14 UTC

Tulu

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

DJ

Loe

23. apr 2026, 22:13 UTC

Tulu

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

DJ

Loe

23. apr 2026, 22:12 UTC

Tulu

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

DJ

Loe

23. apr 2026, 22:12 UTC

Tulu

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

DJ

Loe

23. apr 2026, 22:11 UTC

Tulu

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

DJ

Loe

23. apr 2026, 22:10 UTC

Tulu

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

DJ

Loe

23. apr 2026, 22:09 UTC

Tulu

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

DJ

Loe

23. apr 2026, 22:08 UTC

Tulu

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

DJ

Loe

23. apr 2026, 22:04 UTC

Tulu

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

DJ

Loe

23. apr 2026, 21:56 UTC

Market Talk
Tulu

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

DJ

Loe

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

DJ

Loe

23. apr 2026, 21:27 UTC

Tulu

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

DJ

Loe

23. apr 2026, 21:25 UTC

Tulu

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

DJ

Loe

23. apr 2026, 21:24 UTC

Tulu

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

DJ

Loe

23. apr 2026, 21:24 UTC

Tulu

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

DJ

Loe

23. apr 2026, 21:21 UTC

Tulu

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

DJ

Loe

23. apr 2026, 21:21 UTC

Tulu

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Nektar Therapeutics Prognoos

Hinnasiht

By TipRanks

48.48% tõus

12 kuu keskmine prognoos

Keskmine 138.38 USD  48.48%

Kõrge 185 USD

Madal 95 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Põhineb 8 analüütiku instrumendi Nektar Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5949 / 0.7406Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Strong Bearish Evidence

All events are bearish.

Pikk perspektiiv

Bearish Evidence

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Muud aktsiad sektorist

JNJ

Johnson and Johnson

230.63

↑ +2.12%

ABT

Abbott Laboratories

92.43

↑ +0.79%

MDT

Medtronic PLC

83.72

↑ +0.54%

A

Agilent Technologies Inc

114.27

↓-5.32%

VEEV

Veeva Systems Inc

156.08

↓-4.6%
help-icon Live chat